Probiotic and synbiotic preparations limit growth of multidrug resistant pathogens *in vitro*

Helen Smith[1*], Jose Soto[2], Ronan Power[2], Richard Murphy[1]
[1]Alltech European Bioscience Centre, Summerhill Road, Dunboyne, Co. Meath, Ireland.
[2]Alltech Global Headquarters, 3031 Catnip Hill Rd, Nicholasville, KY 40356, United States.

	Zone of inhibition (mm)				
Bacteria spp.	**Synbiotic 1**	**Synbiotic 2**	**Synbiotic 3**	**Synbiotic 4**	**Antibiotic[1]**
ESBL *E.coli* 13P5	13.67 ± 0.58^{a}	19.67 ± 0.29^{b}	19.50 ± 0.71^{b}	19.17 ± 0.29^{b}	NI
ESBL *E.coli* 25051	14.17 ± 0.76^{a}	19.67 ± 0.58^{c}	19.83 ± 0.76^{c}	16.83 ± 0.29^{b}	NI
MDR *E.coli* ATCC2471	15.33 ± 0.58^{a}	18.50 ± 0.50^{b}	20.33 ± 0.58^{c}	18.33 ± 1.15^{bc}	NI
MDR *Salm.* Dub. CCOS505	17.33 ± 0.58^{a}	19.67 ± 0.29^{b}	19.83 ± 0.29^{b}	19.67 ± 0.58^{b}	41.00 ± 1.41^{c}
***E.coli* ETEC 10674**	20.00 ± 0.00^{c}	17.67 ± 0.58^{a}	19.17 ± 0.76^{bc}	18.67 ± 0.58^{ab}	36.00 ± 1.00^{d}
***E.coli* 0157 10974**	19.67 ± 0.58^{a}	18.50 ± 0.50^{a}	18.67 ± 0.58^{a}	18.33 ± 0.29^{a}	35.83 ± 1.26^{b}
***E.coli* 0157 17076**	18.33 ± 0.58^{a}	18.33 ± 0.58^{a}	21.00 ± 1.00^{b}	19.00 ± 0.50^{a}	35.50 ± 0.87^{c}
***Salm.* Ent. 12694**	18.83 ± 1.04^{a}	19.17 ± 0.29^{a}	19.00 ± 0.50^{a}	19.00 ± 0.00^{a}	39.25 ± 0.35^{b}

Table 1. Zone of inhibition analysis (mm). Analysis based on average and standard deviation of three biological replicates (n = 3). Antibiotic control included per plate (ampicillin 1mgmL^{-1}). Negative control included per plate (0mm). Means that do not share a letter are significantly different per bacteria species (spp.) ($p \leq 0.05$, Tukey's pairwise comparison, ANOVA).
[1]NI; No inhibition due to phenotypic resistance profile.

Abbreviations: ESBL; Extended-spectrum beta-lactamase; *E.coli; Escherichia coli*, MDR; Multidrug resistant, *Salm.; Salmonella, Salm*. Dub.; *Salmonella* Dublin, *E.coli* ETEC; Enterotoxigenic *Escherichia coli, Salm.* Ent.; *Salmonella* Enteritidis